The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.b

Valvular heart disease and/or dysfunction

Publications

Andrejak M, Tribouilloy C

Drug-induced valvular heart disease: an update.

Archives of cardiovascular diseases 2013 May;106;333-9 — 2013 May — 333-9

Bois JP, Ponnada VV, O'Cochlain DF, Brady PA, Edwards WD, Klarich KW

Ergotamine-associated valvulopathy with recurrent chylous pleural effusion.

Texas Heart Institute journal 2012;39;736-8 — 2012 — 736-8

Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J

Drug-induced fibrotic valvular heart disease.

Lancet (London, England) 2009 Aug 15;374;577-85 — 2009 Aug 15 — 577-85

Andersohn F, Garbe E

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 2009 Jan 15;24;129-33 — 2009 Jan 15 — 129-33

Rasmussen VG, Poulsen SH, Dupont E, Østergaard K, Safikhany G, Egeblad H

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.

Journal of internal medicine 2008 Jan;263;90-8 — 2008 Jan — 90-8

Antonini A, Poewe W

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

The Lancet. Neurology 2007 Sep;6;826-9 — 2007 Sep — 826-9

Flowers CM, Racoosin JA, Lu SL, Beitz JG

The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.

Mayo Clinic proceedings 2003 Jun;78;730-1 — 2003 Jun — 730-1

Austin SM, el-Hayek A, Comianos M, Tamulonis DJ

Mitral valve disease associated with long-term ergotamine use.

Southern medical journal 1993 Oct;86;1179-81 — 1993 Oct — 1179-81

Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.

Annals of internal medicine 1992 Jul 01;117;50-2 — 1992 Jul 01 — 50-2